{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:34:02Z","timestamp":1788618842524,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ijcard.2021.03.077","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T21:30:39Z","timestamp":1617831039000},"page":"119-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"332","author":[{"given":"Xuexun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aizhen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2021.03.077_bb0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0010","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0015","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ahj.2014.07.008","article-title":"Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population","volume":"168","author":"Cheng","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0020","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/ehf2.12555","article-title":"Highlights in heart failure","volume":"6","author":"Tomasoni","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ijcard.2021.03.077_bb0025","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","article-title":"Improvement in cardiovascular outcomes with Empagliflozin is independent of glycemic control","volume":"138","author":"Inzucchi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2021.03.077_bb0030","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose Cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0035","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose Cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2021.03.077_bb0040","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0045","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0050","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0055","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0060","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0065","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program","volume":"138","author":"R\u00e5dholm","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2021.03.077_bb0070","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of Dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2021.03.077_bb0075","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2021.03.077_bb0080","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0085","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0090","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","author":"Bhatt","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0095","doi-asserted-by":"crossref","first-page":"e625","DOI":"10.1016\/j.amjmed.2020.04.006","article-title":"Sodium-glucose Cotransporter-2 inhibitors in heart failure: a meta-analysis of randomized clinical trials","volume":"133","author":"Kumar","year":"2020","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0100","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2021.03.077_bb0105","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0110","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"key":"10.1016\/j.ijcard.2021.03.077_bb0115","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of Dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2021.03.077_bb0120","article-title":"Effect of Empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status - results from the EMPEROR-reduced trial","author":"Anker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2021.03.077_bb0125","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ehf2.12505","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions","volume":"6","author":"Lan","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ijcard.2021.03.077_bb0130","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose Cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2021.03.077_bb0135","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.amjcard.2019.08.038","article-title":"Sodium glucose co-transporter 2 inhibitors and heart failure","volume":"124","author":"Ghosh","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0140","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0145","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2021.03.077_bb0150","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11886-019-1219-4","article-title":"Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors","volume":"21","author":"Wojcik","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2021.03.077_bb0155","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.amjcard.2019.10.026","article-title":"Preventing and treating heart failure with sodium-glucose co-transporter 2 inhibitors","volume":"124","author":"Vaduganathan","year":"2019","journal-title":"Am. J. Cardiol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527321006367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527321006367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:52:41Z","timestamp":1759092761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527321006367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":31,"alternative-id":["S0167527321006367"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.03.077","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.03.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}